Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.

Fricke SL, Payne SN, Favreau PF, Kratz JD, Pasch CA, Foley TM, Yueh AE, Van De Hey DR, Depke MG, Korkos DP, Sha GC, DeStefanis RA, Clipson L, Burkard ME, Lemmon KK, Parsons BM, Kenny PA, Matkowskyj KA, Newton MA, Skala MC, Deming DA.

Mol Cancer Ther. 2019 Feb;18(2):346-355. doi: 10.1158/1535-7163.MCT-18-0510. Epub 2018 Nov 13.

PMID:
30425131
2.

Protein-bound NAD(P)H Lifetime is Sensitive to Multiple Fates of Glucose Carbon.

Sharick JT, Favreau PF, Gillette AA, Sdao SM, Merrins MJ, Skala MC.

Sci Rep. 2018 Apr 3;8(1):5456. doi: 10.1038/s41598-018-23691-x.

3.

Hyperspectral imaging fluorescence excitation scanning for colon cancer detection.

Leavesley SJ, Walters M, Lopez C, Baker T, Favreau PF, Rich TC, Rider PF, Boudreaux CW.

J Biomed Opt. 2016 Oct 1;21(10):104003. doi: 10.1117/1.JBO.21.10.104003.

4.

Excitation-scanning hyperspectral imaging microscope.

Favreau PF, Hernandez C, Heaster T, Alvarez DF, Rich TC, Prabhat P, Leavesley SJ.

J Biomed Opt. 2014 Apr;19(4):046010. doi: 10.1117/1.JBO.19.4.046010.

Supplemental Content

Loading ...
Support Center